You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SKF 82958 hydrobromide
D1 agonist. Increases renal blood flow in animal models and promotes contralateral rotation in rats with unilateral lesions of the substantia nigra. Also augments GABAB inhibitory post-synaptic potentials (ipsp) in ventral tegmental area in brain slices.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.05||5 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 410.73. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.43 mL||12.17 mL||24.35 mL|
|5 mM||0.49 mL||2.43 mL||4.87 mL|
|10 mM||0.24 mL||1.22 mL||2.43 mL|
|50 mM||0.05 mL||0.24 mL||0.49 mL|
References are publications that support the biological activity of the product.
Pfeiffer et al (1982) DArgic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines. J.Med.Chem. 25 352 PMID: 7069713
Cameron and Williams (1993) DA D1 receptors facilitate transmitter release. Nature 366 344 PMID: 8247128
If you know of a relevant reference for SKF 82958 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: SKF 82958 hydrobromide, SKF 82958 hydrobromide supplier, SKF82958, hydrobromide, dopamine, D1, agonists, agonism, and, D5, Receptors, 5719, Tocris Bioscience
1 Citation for SKF 82958 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 82958 hydrobromide include:
Verharen et al (2019) Differential contributions of striatal dopamine D1 and D2 receptors to component processes of value-based decision making. Neuropsychopharmacology 44 2195 PMID: 31254972
Do you know of a great paper that uses SKF 82958 hydrobromide from Tocris? Please let us know.
Reviews for SKF 82958 hydrobromide
There are currently no reviews for this product. Be the first to review SKF 82958 hydrobromide and earn rewards!
Have you used SKF 82958 hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.